Catabasis Pharmaceuticals (NASDAQ:CATB) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Friday. The firm presently has a $1.75 price target on the biotechnology company’s stock. Zacks Investment Research‘s price target points to a potential upside of 11.46% from the stock’s current price.

According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “

Other research analysts also recently issued reports about the company. Citigroup set a $3.50 target price on Catabasis Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, October 5th. CIBC reiterated an “outperform” rating and set a $7.00 target price (up from $4.00) on shares of Catabasis Pharmaceuticals in a research report on Thursday, October 5th. Oppenheimer increased their target price on Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the company an “outperform” rating in a research report on Thursday, October 5th. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, December 15th. Finally, Cowen reiterated a “market perform” rating and set a $2.00 target price on shares of Catabasis Pharmaceuticals in a research report on Friday, October 6th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $4.82.

Catabasis Pharmaceuticals (CATB) traded down $0.04 during midday trading on Friday, hitting $1.57. The stock had a trading volume of 281,634 shares, compared to its average volume of 207,351. The company has a market cap of $36.24, a P/E ratio of -1.04 and a beta of 1.26. Catabasis Pharmaceuticals has a 52-week low of $1.08 and a 52-week high of $5.51.

Catabasis Pharmaceuticals (NASDAQ:CATB) last posted its earnings results on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.02. The firm had revenue of $0.25 million for the quarter. sell-side analysts predict that Catabasis Pharmaceuticals will post -1.37 earnings per share for the current fiscal year.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Wedbush Securities Inc. lifted its position in Catabasis Pharmaceuticals by 2,368.6% in the third quarter. Wedbush Securities Inc. now owns 251,802 shares of the biotechnology company’s stock worth $534,000 after buying an additional 241,602 shares during the last quarter. Virtu KCG Holdings LLC bought a new stake in Catabasis Pharmaceuticals in the second quarter worth $271,000. Oppenheimer & Co. Inc. lifted its position in Catabasis Pharmaceuticals by 40.8% in the third quarter. Oppenheimer & Co. Inc. now owns 169,000 shares of the biotechnology company’s stock worth $358,000 after buying an additional 49,000 shares during the last quarter. Finally, Renaissance Technologies LLC bought a new stake in Catabasis Pharmaceuticals in the first quarter worth $106,000. Institutional investors own 32.31% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Catabasis Pharmaceuticals (CATB) Rating Increased to Buy at Zacks Investment Research” was first published by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international trademark & copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/catabasis-pharmaceuticals-catb-rating-increased-to-buy-at-zacks-investment-research/1797947.html.

Catabasis Pharmaceuticals Company Profile

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Get a free copy of the Zacks research report on Catabasis Pharmaceuticals (CATB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Catabasis Pharmaceuticals (NASDAQ:CATB)

Receive News & Ratings for Catabasis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.